

Supplementary Figure 3. Lung adenocarcinoma molecular signatures of FVB mice. A, Schematic of urethane administration in FVB mice: one intraperitoneal injection of 1 g/Kg urethane (grey arrow) was administered at six weeks after birth (pink arrow) and lungs were examined six months later (black arrow). **B**, Representative photographs and epifluorescence images of tumor-bearing mT/mG, mT/mG; Scgb1a1. Cre, mT/mG; Sftpc. Cre, and mTmG; Lyz2. Cre FVB lungs ($n \ge 8$ /group). Arrows indicate lung tumors. Note the absence of mG+ fluorescence in mT/mG tumors, the mG+ fluorescence of mT/mG; Scgb1a1.Cre and mT/mG; Sftpc.Cre tumors, and the split mG+ and mGtumors of mTmG;Lyz2.Cre mice. C, Lineage marker protein-stained LUAD (dashed outlines) from genetically-marked mice from D (FVB, $n \ge 10$ /group). Note mG+CCSP-SFTPC+LYZ2± LUAD cells of mTmG; Scgb1a1. Cre mice. **D**, Lineage marker-stained lung sections of 6-week-old lungmarked mice (FVB, n = 5/group). Note mG+CCSP+ club and mG+TUBA1A+ ciliated cells in bronchi (b) of mT/mG; Scgb1a1.Cre mice, mG+SFTPC+LYZ2± alveolar type II cells and mG+SFTPC-LYZ2+ alveolar macrophages in the alveoli (a) of mT/mG;Lyz2.Cre mice, and various mG+ cells in bronchi and alveoli of mT/mG; Sftpc. Cre mice. Arrows indicate lineage marker protein-expressing mG+ (green) and mT+ (red) cells. Five non-overlapping fields/sample were examined. mG, membranous green fluorescent protein fluorophore; mT, membranous tomato fluorophore; CCSP, Clara cell secretory protein; SFTPC, surfactant protein C; LYZ2, lysozyme 2.